In about 20% of patients with AML, excluding acute promyelocytic leukemia (APL), distinct fusion genes are approachable for MRD monitoring with most of them represented by core-binding factor (CBF) AML (RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes) [1,12,13,59]. The gene discussed is MYH11; the disease is acute promyelocytic leukemia.